AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04388423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulated puncture training
Description: The residents are trained of simulated puncture : 1.the location puncture; 2. finding fixed-point needle on the model for 5 times, each time for 30 minutes.
Study NCT04388423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional bedside teaching
Description: The residents are trained by traditional bedside teaching
Study NCT01781247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal behavioral intervention
Description: The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
Study NCT01781247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided.
Study NCT02020642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Description: Renal transplantation from cadaveric or live donor
Study NCT01518062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 4 IU/m\^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
Study NCT01518062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
Study NCT01518062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Initial dose 4 IU/m\^2 body surface the first year, then 6 IU/m\^2 body surface, the second year and finally 8 IU/m\^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
Study NCT01518062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oestrogen
Description: Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
Study NCT03661775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate administration
Description: controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
Study NCT00374868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Phase 1: 300 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m\^2, 400 mg/m\^2, and 500 mg/m\^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy
Study NCT00374868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Phase 1: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m\^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy
Study NCT04751266 — intervention group
Intervention type: PROCEDURE
Intervention: minimally invasive repair of pectus excavatum
Description: substernal insertion of a metal bar
Study NCT00614679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
Description: N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Attending real-time decision support
Description: Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-room real-time decision support
Description: Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
Study NCT00166699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: The use of ultrasound to guide the insertion of combined spinal epidural needle
Study NCT02722967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole + IEM (Ingestible Event Marker)
Description: Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
Study NCT01508000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX6
Description: 5-FU, folinic acid, oxaliplatin
Study NCT01508000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: 5-FU, folinic acid, oxaliplatin
Study NCT01508000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Targeted therapy
Study NCT01508000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Targeted therapy
Study NCT01508000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study NCT01508000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Attending feedback emails
Description: Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-room provider feedback emails
Description: In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
Study NCT02726620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia Information Management System (AIMS)
Description: The anesthesia electronic record keeping system
Study NCT02726620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioperative Data Warehouse (PDW)
Description: The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
Study NCT02062593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty
Description: Percutaneous coronary intervention with drug-eluting stents and modern techniques
Study NCT02062593 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Coronary angioplasty
Description: Percutaneous coronary intervention with drug-eluting stents and modern techniques
Study NCT02708329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-provisional stenting
Description: Standard endovascular T-provisional stenting technique
Study NCT02708329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini-crush stenting
Description: Standard endovascular Mini-crush stenting technique
Study NCT02708329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO coronary angioplasty
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
Study NCT02708329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTO coronary angioplasty
Description: A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
Study NCT00591721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy conservation education
Description: The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
Study NCT00591721 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Energy conservation education
Description: The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
Study NCT02279628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
Study NCT02279628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
Study NCT02279628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
Study NCT04403464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE with REAtouch®
Description: 65h HABIT-ILE including 30h REAtouch®
Study NCT04403464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HABIT-ILE without REAtouch®
Description: 65h HABIT-ILE
Study NCT02726620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pager system
Description: The mobile pager system through which alerts can be sent
Study NCT03410316 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03776045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care plus exercise
Description: The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted \~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
Study NCT02138383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
Study NCT02138383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The starting dose of gemcitabine will be 1000 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
Study NCT02138383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: The starting dose of nab-paclitaxel will be 125 mg/m\^2 administered intravenously on days 1, 8 and 15 of each cycle.
Study NCT03514953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Physical Activity
Description: Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns.
Study NCT01745510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Docosahexaenoic acid from algae source
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central neuraxial anesthesia
Description: Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central neuraxial anesthesia
Description: Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cardiac surgery
Description: Any surgical intervention that is not aimed at surgical correction of the heart
Study NCT01745510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was designed to mimic the color and consistence of the oil that contains DHA
Study NCT00169832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone or placebo
Description: Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
Study NCT00169832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone or placebo
Description: Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
Study NCT00581555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg QW initiated during taper of ciclosporin
Study NCT00581555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to placebo during taper of ciclosporin
Study NCT03831126 — intervention group
Intervention type: DRUG
Intervention: Betamethason Sodium Phosphate
Description: First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
Study NCT00504400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection ranibizumab
Description: Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
Study NCT03274817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Pill
Description: Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
Study NCT03274817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Pill
Description: Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
Study NCT00509691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytomegalovirus pp65-specific cytotoxic T lymphocytes
Study NCT00509691 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study NCT01819636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sparkling highly mineral bicarbonated sodium water
Description: 1,25 liter a day at the mealtimes
Study NCT00509691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT03274817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
Study NCT02759458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Healicoil Anchor
Study NCT02759458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smith & Nephew Twinfix Anchor
Study NCT01351636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arotinolol Hydrochloride
Description: Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
Study NCT01351636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non arotinolol group
Description: Antihypertensive medications without arotinolol for 18 months
Study NCT02642900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy
Description: evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
Study NCT02642900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin 100.000 units
Description: Control group treated with nystatin
Study NCT02726620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-cardiac surgery
Description: Any surgical intervention that is not aimed at surgical correction of the heart
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Anesthetic drug used to maintain general anesthesia
Study NCT02726620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Anesthetic drug used to maintain general anesthesia